Open Targets was founded by three global leading institutions in the fields of pharmaceuticals, bioinformatics and genomics, GSK, EMBL-EBI, the Wellcome Trust Sanger Institute, and recently joined by Biogen, the world’s oldest independent biotechnology company.

We combine large-scale genomic experiments with objective statistical and computational techniques to identify and validate the causal links between targets, pathways and diseases. Cross-cutting several therapeutic areas, we generate cellular models of disease through gene editing technologies or single cell analysis. In addition to clinical samples, iPS cells and cellular organoids are resourced to provide cellular phenotyping with high physiological relevance. Open Targets integrates comprehensive datasets from a myriad of renowned public databases, such as UniProt, ChEMBL, Ensembl, NHGRI-EBI GWAS, EuropePMC, COSMIC, GTEx, among others. The data and analytical processes are developed by a set of interlinking projects.

The purpose of this half-day workshop is to acquaint participants with the Open Targets project and its Target Validation interface and introduce the tools for visualisation and interpretation of gene-disease associations and target validation based on a comprehensive platform with data from various publicly available databases. By the end of this half-day workshop, users will be able to carry out effective searches of data, use the web application to visualise genes, variants, ontology, pathways (and more) in the context of human disease and therapeutics.

Please note that if you are not eligible for a University of Cambridge Raven account you will need to Book or register Interest by linking here.''